Inogen (NASDAQ:INGN – Get Free Report)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports.
Separately, StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, December 20th.
Read Our Latest Analysis on Inogen
Inogen Stock Up 6.0 %
Inogen (NASDAQ:INGN – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical technology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.26. The firm had revenue of $88.83 million during the quarter, compared to analyst estimates of $83.68 million. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. During the same quarter in the previous year, the business posted ($1.97) EPS. On average, equities research analysts anticipate that Inogen will post -1.73 earnings per share for the current fiscal year.
Institutional Trading of Inogen
Several large investors have recently bought and sold shares of INGN. Quarry LP purchased a new stake in Inogen during the 3rd quarter worth approximately $59,000. Verition Fund Management LLC purchased a new stake in shares of Inogen in the 3rd quarter valued at $106,000. Virtu Financial LLC purchased a new stake in shares of Inogen in the 3rd quarter valued at $111,000. Paloma Partners Management Co purchased a new stake in shares of Inogen in the 3rd quarter valued at $126,000. Finally, Centiva Capital LP purchased a new stake in shares of Inogen in the 3rd quarter valued at $138,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
- Five stocks we like better than Inogen
- The 3 Best Fintech Stocks to Buy Now
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- Find and Profitably Trade Stocks at 52-Week Lows
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.